{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:06:17Z","timestamp":1779815177287,"version":"3.53.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urology.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:23:10Z","timestamp":1770855790000},"page":"53-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study"],"prefix":"10.1016","volume":"211","author":[{"given":"Angela B.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chisolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.02.006_bib1","unstructured":"American Cancer Society. Key statistics for bladder cancer. March 12, 2024. Accessed November 13, 2024. https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html."},{"key":"10.1016\/j.urology.2026.02.006_bib2","unstructured":"Global Cancer Observatory. Cancer today: age-standardized rate (world) per 100 000, incidence, both sexes, in 2022. 2022. Accessed November 27, 2024. https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/bars?mode=cancer&group_populations=1."},{"key":"10.1016\/j.urology.2026.02.006_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.02.006_bib4","unstructured":"Urology EA. 2025 EAU Guidelines on Non-muscle-invasive Bladder Cancer; 2025. Accessed June 10, 2025. \u3008https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer\/\u3009."},{"key":"10.1016\/j.urology.2026.02.006_bib5","doi-asserted-by":"crossref","first-page":"12596","DOI":"10.3390\/ijms241612596","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets","volume":"24","author":"Claps","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urology.2026.02.006_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urology.2026.02.006_bib7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","article-title":"Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort","volume":"81","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.02.006_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.21037\/atm.2019.10.24","article-title":"PD-L1 assessment in urothelial carcinoma: a practical approach","volume":"7","author":"Eckstein","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.urology.2026.02.006_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.26841.1","article-title":"New and emerging therapies in the management of bladder cancer","volume":"9","author":"Osterman","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.urology.2026.02.006_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health \u2013 a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.urology.2026.02.006_bib11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.urology.2026.02.006_bib12","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/cncr.31530","article-title":"Patient-centered prioritization of bladder cancer research","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2026.02.006_bib13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/0284186X.2020.1762926","article-title":"Cancer patients' preferred and perceived level of involvement in treatment decision-making: an epidemiological study","volume":"59","author":"Hahlweg","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.urology.2026.02.006_bib14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1186\/s12885-023-11605-8","article-title":"Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer","volume":"23","author":"Gore","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urology.2026.02.006_bib15","first-page":"1","article-title":"The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: lessons learned about management and patient enrollment in a large, pragmatic, patient-centered trial","author":"Nathan","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2026.02.006_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euros.2022.12.016","article-title":"Patient preferences for treatment of Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: a cross-country choice experiment","volume":"49","author":"Collacott","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urology.2026.02.006_bib17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2026.02.006_bib18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.32604\/or.2025.061812","article-title":"Intradermal priming to intravesical Bacillus Calmette-Gu\u00e9rin in non-muscle invasive bladder cancer: a translational research and phase I clinical trial","volume":"33","author":"Saboya","year":"2025","journal-title":"Oncol Res"},{"key":"10.1016\/j.urology.2026.02.006_bib19","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/14796694.2024.2363744","article-title":"N-803 plus BCG treatment for BCG-Na\u00efve or -unresponsive non-muscle invasive bladder cancer: a plain language review","volume":"20","author":"Chamie","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.urology.2026.02.006_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force","volume":"16","author":"Reed Johnson","year":"2013","journal-title":"Value Health"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526000920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526000920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:43:30Z","timestamp":1779813810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526000920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"alternative-id":["S0090429526000920"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.02.006","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}